France indapamide market is estimated to grow significantly at a CAGR of around 3.5% during the forecast period. France indapamide market is being primarily driven by the increasing incidence of stroke and the rising hypertension cases in the country. As per the UN (United Nation), in 2019, there were 13.3 million people aged 65 years or over, which is 20.4% of the total population. Nearly 24.1% of the population is expected to be aged 65 years or over by 2030, which will be nearly 16.1 million people. Moreover, it is estimated that a 40.0% increase in stroke incidence will be witnessed during 2015 and 2030 and a 30.0% increase in prevalence, and 51% increment in mortality Owing to this significant rise in the aging population, a significant demand for the treatment of strokes is expected to arise in the upcoming period that further encourages the demand for indapamide in the country.
France indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the France indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the France indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. France Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. France Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Company Profiles
6.1. Bioindustria L.I.M. S.p.A.
6.2. Grupo Azevedos
6.3. Krka Group
6.4. Laboratori Baldacci S.p.A.
6.5. Merck KGaA
6.6. Mylan N.V.
6.7. Sandoz International GmbH
6.8. Sanofi S.A.
6.9. Servier Group
6.10. Teva Pharmaceuticals Industries Ltd.
1. FRANCE INDAPAMIDE MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2019-2026 ($ MILLION)
2. FRANCE INDAPAMIDE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. FRANCE INDAPAMIDE MARKET SHARE BY PRODUCT, 2019 VS 2026 (%)
2. FRANCE INDAPAMIDE MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)